18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

Official Title

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

Summary:

Single centre prospective cohort phase III study of 18F-DOPA PET/CT imaging in specific patient populations:
1. Pediatric patients with congenital hyperinsulinism
2. Pediatric patients with neuroblastoma
3. Pediatric or Adult patients with suspected extra-pancreatic neuroendocrine tumour
4. Adult patients with a clinical suspicion of Parkinson's disease
5. Pediatric or Adult patients with primary brain tumours
This study will evaluate the biodistribution and safety of 18F-DOPA produced at the Edmonton PET Centre.

Trial Description

Primary Outcome:

  • Immediate safety evaluation
Secondary Outcome:
  • Delayed safety evaluation
  • Delayed safety evaluation - referring physician
  • Biodistribution: scan interpreter will evaluate the distribution of tracer and comment if expected
  • Perceived clinical benefit

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society